Global Statistics

All countries
240,231,299
Confirmed
Updated on October 14, 2021 7:22 pm
All countries
215,802,873
Recovered
Updated on October 14, 2021 7:22 pm
All countries
4,893,546
Deaths
Updated on October 14, 2021 7:22 pm

Global Statistics

All countries
240,231,299
Confirmed
Updated on October 14, 2021 7:22 pm
All countries
215,802,873
Recovered
Updated on October 14, 2021 7:22 pm
All countries
4,893,546
Deaths
Updated on October 14, 2021 7:22 pm

Rifadin (rifampin, isoniazid and pyrazinamide) for TB: Side Effects & Warnings

What is Rifadin (rifampin, isoniazid and pyrazinamide), and what is it used for?

Brand name: Rifadin

Generic: rifampin, isoniazid and pyrazinamide

Rifadin is an antibiotic used to treat tuberculosis (TB).

What are the side effects of Rifadin?

Common side effects of Rifadin include:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of
Rifadin (rifampin capsules USP) and Rifadin IV (rifampin for injection USP) and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Is Rifadin addictive?

No information provided

What drugs interact with Rifadin?

Pharmacodynamic Interactions

  • Healthy subjects who received rifampin 600 mg once daily concomitantly with saquinavir 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted saquinavir) developed severe hepatocellular toxicity. Therefore, concomitant use of these medications is contraindicated.
  • When rifampin is given concomitantly with other hepatotoxic medications such as halothane or isoniazid, the potential for hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepatotoxicity.

Effect Of Rifampin On Other Drugs

Induction Of Drug Metabolizing Enzymes And Transporters

Drug metabolizing enzymes and transporters affected by rifampin include cytochromes P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, and 3A4, UDP-glucuronyltransferases (UGT), sulfotransferases, carboxylesterases, and transporters including P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2).

Most drugs are substrates for one or more of these enzyme or transporter pathways and these pathways may be induced by rifampin simultaneously. Therefore, rifampin may increase the metabolism and decrease the activity of certain coadministered drugs or increase the activity of a coadministered pro-drug (where metabolic activation is required) and has the potential to perpetuate clinically important drug drug interactions against many drugs and across many drug classes (Table 1).

Table 1 summarizes the effect of rifampin on other drugs or drug classes. Adjust dosages of concomitant drugs based on approved drug labeling and if applicable, therapeutic drug monitoring, unless otherwise specified.

Table 1: Drug Interactions with Rifampin that Affect Concomitant Drug Concentrationsa

Drug or Drug Class and Prevention or Management
Clinical Effect

Antiretrovirals
Prevention or Management: Concomitant use is contraindicated

Atazanavir
Decrease AUC by 72%

Darunavirb

Tipranavir
Substantial decrease in exposure, which may result in loss of therapeutic effect and development of resistance.

Fosamprenavirc
Decrease AUC by 82%

Saquinavir
Decrease AUC by 70% Coadministration may result in severe hepatocellular toxicity

Antiretrovirals
Prevention or Management: Avoid concomitant use

Zidovudine
Decrease AUC by 47%

Indinavir
Decrease AUC by 92%

Efavirenz
Decrease AUC by 26%

Hepatitis C Antiviral
Prevention or Management: Avoid concomitant use

Daclatasvir
Decrease AUC by 79%

Simeprevir
Decrease AUC by 48%

Sofosbuvirb
Decrease AUC by 72% Coadministration of sofosbuvir with rifampin, may decrease sofosbuvir plasma concentrations, leading to reduced therapeutic effect of sofosbuvir.

Telaprevir
Decrease AUC by 92%

Systemic Hormonal Contraceptives
Prevention or Management: Advise patients to change to non-hormonal methods of birth control during rifampin therapy

Estrogens
Decrease exposure

Progestins

Anticonvulsants

Phenytoind
Decrease exposured

Antiarrhythmics

Disopyramide
Decrease exposure

Mexiletine
Decrease exposure

Quinidine
Decrease exposure

Propafenone
Decrease AUC by 50%-67%

Tocainide
Decrease exposure

Antiestrogens

Tamoxifen
Decrease AUC by 86%

Tamoxifen
Decrease steady state concentrations of toremifene in serum

Antithrombotic Agents

Clopidogrel
Prevention or Management: Concomitant use of clopidogrel and rifampin should be discouraged
Increase active metabolite exposure and risk of
bleeding

Ticagrelor
Prevention or Management: Avoid use
Decrease exposure

Antipsychotics

Haloperidol
Decrease plasma concentrations by 70%

Oral Anticoagulants
Prevention or Management: Perform prothrombin time daily or as frequently as necessary to establish and maintain the required dose of anticoagulant

Warfarin
Decrease exposure

Antifungals

Fluconazole
Decrease AUC by 23%

Itraconazole
Prevention or Management: Not recommended 2 weeks before and during itraconazole treatment
Decrease exposure

Ketoconazole
Decrease exposure

Beta-blockers

Metoprolol
Decrease exposure

Propranolol
Decrease exposure

Benzodiazepines

Diazepama,e
Decrease exposure

Benzodiazepine-related drugs

Zopiclone
Decrease AUC by 82%

Zolpidem
Decrease AUC by 73%

Calcium Channel Blockerse

Diltiazem
Decrease exposure

Nifedipinef
Decrease exposure

Verapamil
Decrease exposure

Corticosteroidsg

Prednisolone
Decrease exposure

Cardiac Glycosides

Digoxin
Prevention or Management: Measure serum digoxin
concentrations before initiating rifampin. Continue monitoring and increase digoxin dose by
approximately 20%-40% as necessary.
Decrease exposure

Digitoxin
Decrease exposure

Fluoroquinolones

Pefloxacinh
Decrease exposure

Moxifloxacina,d
Decrease exposure

Oral Hypoglycemic Agents (e.g. sulfonylureas)

Glyburide
Decrease exposure Rifampin may worsen glucose control of glyburide

Glipizide
Decrease exposure

Immunosuppressive Agents

Cyclosporine
Decrease exposure

Tacrolimus
Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage
adjustments of tacrolimus are recommended when
rifampin and tacrolimus are used concomitantly.
Decrease AUC by 56%

Narcotic Analgesics

Oxycodone
Decrease AUC by 86%

Morphine
Decrease exposure

Selective 5-HT3 Receptor Antagonists

Ondansetron
Decrease exposure

Statins Metabolized by CYP3A4

Simvastatin
Decrease exposure

Thiazolidinediones

Rosiglitazone
Decrease AUC by 66%

Tricyclic Antidepressants

Nortriptylinei
Decrease exposure

Other Drugs

Enalapril
Decrease active metabolite exposure

Chloramphenicolj
Decrease exposure

Clarithromycin
Decrease exposure

Dapsone
Decrease exposure

Doxycyclinek
Decrease exposure

Irinotecanl
Prevention or Management: Avoid the use of rifampin, strong CYP3A4 inducer, if possible. Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy
Decrease irinotecan and active metabolite exposure

Levothyroxine
Decrease exposure

Losartan
Parent
Decrease AUC by 30%

Active metabolite (E3174)
Decrease AUC by 40%

Methadone
In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.

Praziquantel
Prevention or Management: Concomitant use is contraindicated
Decrease plasma praziquantel concentrations to undetectable levels.

Quinine
Prevention or Management: Avoid concomitant use
Decrease AUC by 75%-85%

Telithromycin
Decrease AUC by 86%

Theophylline
Decrease exposure by 20% to 40%

a Administered with rifampin 600 mg daily, unless otherwise specified
b Rifampin dosage used concomitantly with the drug(s) is not specified in the proposed package insert.
c Administered with rifampin 300 mg daily
d Administered with rifampin 450 mg daily
e Administered with rifampin 1200 mg daily
f Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg
g Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. The literature contains reports of acute adrenal crisis or adrenal insufficiency induced by the combination of rifampin-isoniazid-ethambutol or rifampin-isoniazid in patients with Addison’s disease
h Administered with rifampin 900 mg daily
i A tuberculosis treatment regimen including rifampin (600 mg/day) isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was associated with higher than expected doses of nortriptyline were required to obtain a therapeutic drug level. Following the discontinuation of rifampin, the patient became drowsy and the serum nortriptyline levels rose precipitously (3-fold) into the toxic range.
j Concomitant use with rifampin in 2 children
k Administered with rifampin (10 mg/kg daily)
l Administered with an antibiotic regimen including rifampin (450 mg/day), isoniazid (300 mg/day), and streptomycin (0.5 g/day) IM
AUC = area under the time-concentration curve

Effect Of Other Drugs On Rifampin

  • Concomitant antacid administration may reduce the absorption of rifampin. Daily doses of rifampin should be given at least 1 hour before the ingestion of antacids.
  • Concomitant use with probenecid and cotrimoxazole increases the concentration of rifampin which may increase the risk of Rifadin toxicities. Monitor for adverse reactions associated with Rifadin during coadministration.

Other Interactions

Atovaquone
  • Concomitant use of rifampin with atovaquone decrease concentrations of atovaquone and increase concentrations of rifampin which may increase the risk of Rifadin toxicities. Coadministration of rifampin with atovaquone is not recommended.




QUESTION

Bowel regularity means a bowel movement every day.
See Answer

What is the dosage for Rifadin?

Rifampin can be administered by the oral route or by IV infusion. IV doses are the same as those for oral.

See prescribing information for dosing information in patients with renal failure.

Tuberculosis

Adults
  • 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or IV
Pediatric Patients
  • 10-20 mg/kg, not to exceed 600 mg/day, oral or IV
  • It is recommended that oral rifampin be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.
  • Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., Rifater) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
  • Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
Preparation Of Solution For IV Infusion
  • Reconstitute the lyophilized powder by transferring 10 mL of sterile water for injection to a vial containing 600 mg of rifampin for injection. Swirl vial gently to completely dissolve the antibiotic. The reconstituted solution contains 60 mg rifampin per mL and is stable at room temperature for up to 30 hours. Prior to administration, withdraw from the reconstituted solution a volume equivalent to the amount of rifampin calculated to be administered and add to 500 mL of infusion medium. Mix well and infuse at a rate allowing for complete infusion within 3 hours. Alternatively, the amount of rifampin calculated to be administered may be added to 100 mL of infusion medium and infused in 30 minutes.
  • Dilutions in dextrose 5% for injection (D5W) are stable at room temperature for up to 8 hours and should be prepared and used within this time. Precipitation of rifampin from the infusion solution may occur beyond this time. Dilutions in normal saline are stable at room temperature for up to 6 hours and should be prepared and used within this time. Other infusion solutions are not recommended.
Incompatibilities
  • Physical incompatibility (precipitate) was observed with undiluted (5 mg/mL) and diluted (1 mg/mL in normal saline) diltiazem hydrochloride and rifampin (6 mg/mL in normal saline) during simulated Y-site administration.

Meningococcal Carriers

Adults
  • For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.
Pediatric Patients
  • Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.
Pediatric Patients Under 1 Month Of Age
  • 5 mg/kg every 12 hours for two days.

Rifadin contraindications, and pregnancy and breastfeeding safety

  • Rifadin should be used with caution in patients with a history of diabetes mellitus, as diabetes management may be more difficult.
  • When administered during the last few weeks of pregnancy, rifampin can cause postnatal hemorrhages in the mother and infant for which treatment with vitamin K may be indicated.
  • Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Hot Topics

Related Articles